Nucleai Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
72
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Nucleai General Information
Description
Developer of a spatial biology software platform intended for precision medicine, and aims to transform healthcare through artificial intelligence. The company's AI-based technology improves biopsy interpretation with machine learning, creates novel precision medicine technology, and uses computer vision and machine learning algorithms to detect signs of cancer and gastrointestinal diseases as well as enhance drug development support treatment decisions and improve patient lives, enabling researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.
Contact Information
Website
nucleai.aiCorporate Office
- 400 North Aberdeen Street
- Suite 951
- Chicago, IL 60642
- United States
Corporate Office
- 400 North Aberdeen Street
- Suite 951
- Chicago, IL 60642
- United States
Nucleai Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 6. Later Stage VC (Series B) | 03-Apr-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 22-Mar-2022 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 13-Jul-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 07-Jul-2020 | Completed | Generating Revenue | |||
| 2. Seed Round | 05-Mar-2018 | $5M | $5M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Nucleai Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B | ||||||||
| Preferred A | ||||||||
| Seed | 25,531,916 | $0.23 | $0.23 | 1x | $0.23 | 21.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nucleai Comparisons
Industry
Financing
Details
Nucleai Competitors (36)
One of Nucleai’s 36 competitors is PreciseDx, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PreciseDx | Venture Capital-Backed | New York, NY | ||||
| PredxBio | Venture Capital-Backed | Pittsburgh, PA | ||||
| Ibex Medical Analytics | Venture Capital-Backed | Tel Aviv, Israel | ||||
| Idoven | Venture Capital-Backed | Madrid, Spain | ||||
| RADLogics | Venture Capital-Backed | New York, NY |
Nucleai Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nucleai Patents
Nucleai Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026028203-A1 | A system and method of categorizing protein expression in biological cells | Pending | 30-Jul-2024 | ||
| US-20250259419-A1 | Selection of targets for drug development | Pending | 08-Feb-2024 | ||
| EP-4824746-A1 | System and method of identifying a tertiary lymphoid structure | Pending | 11-Dec-2023 | ||
| US-20260321038-A1 | System and method of identifying a tertiary lymphoid structure | Pending | 11-Dec-2023 | ||
| WO-2025126205-A1 | System and method of identifying a tertiary lymphoid structure | Inactive | 11-Dec-2023 | G06T7/0012 |
Nucleai Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nucleai Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| M Ventures | Corporate Venture Capital | Minority | ||
| S32 | Venture Capital | Minority | ||
| Scale Asia Ventures | Venture Capital | Minority | ||
| Fosun RZ Capital | Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority |
Nucleai FAQs
-
When was Nucleai founded?
Nucleai was founded in 2017.
-
Where is Nucleai headquartered?
Nucleai is headquartered in Chicago, IL.
-
What is the size of Nucleai?
Nucleai has 72 total employees.
-
What industry is Nucleai in?
Nucleai’s primary industry is Decision/Risk Analysis.
-
Is Nucleai a private or public company?
Nucleai is a Private company.
-
What is Nucleai’s current revenue?
The current revenue for Nucleai is .
-
How much funding has Nucleai raised over time?
Nucleai has raised $60.5M.
-
Who are Nucleai’s investors?
M Ventures, S32, Scale Asia Ventures, Fosun RZ Capital, and Sanofi Ventures are 5 of 11 investors who have invested in Nucleai.
-
Who are Nucleai’s competitors?
PreciseDx, PredxBio, Ibex Medical Analytics, Idoven, and RADLogics are some of the 36 competitors of Nucleai.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
